Bae Sun Hyun, Kim Mi-Sook, Jang Won Il, Kay Chul-Seung, Kim Woochul, Kim Eun Seog, Kim Jin Ho, Kim Jin Hee, Yang Kwang Mo, Lee Kyu Chan, Chang A Ram, Jo Sunmi
Department of Radiation Oncology, Soonchunhyang University College of Medicine, Bucheon.
Korea Institute of Radiological & Medical Sciences, Seoul
Jpn J Clin Oncol. 2016 Apr;46(4):363-9. doi: 10.1093/jjco/hyv209. Epub 2016 Jan 29.
To investigate practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea.
In June 2013, the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology conducted a national patterns-of-care survey about stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma, consisting of 19 questions and 2 clinical scenarios.
All 208 radiation oncologists (100%), who are regular members of Korean Society for Radiation Oncology, responded to this survey. Among these, 95 radiation oncologists were specialists for hepatology; 64 physicians did not use stereotactic body radiotherapy for hepatocellular carcinoma, and 31 physicians used stereotactic body radiotherapy. Most physicians (52%) performed stereotactic body radiotherapy to hepatocellular carcinoma in ≤5 cases per year. Physicians applied stereotactic body radiotherapy according to tumour size and baseline Child-Pugh class. All physicians agreed the use of stereotactic body radiotherapy to 2.8-cm hepatocellular carcinoma with Child-Pugh class of A, while 23 physicians (74%) selected stereotactic body radiotherapy for Child-Pugh class of B. Nineteen physicians (61%) selected stereotactic body radiotherapy to 5-cm hepatocellular carcinoma with Child-Pugh class of A, and only 14 physicians (45%) selected stereotactic body radiotherapy for Child-Pugh class of B. On the other hand, the preferred dose scheme was same as 60 Gy in three fractions.
Among radiation oncologists in Korea, there was diversity in the practice for stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma. Additional prospective studies are necessary to standardize the practice and establish Korea-specific practice guidelines for hepatocellular carcinoma stereotactic body radiotherapy.
探讨韩国肝细胞癌立体定向体部放射治疗的实际模式。
2013年6月，韩国放射肿瘤学会的韩国立体定向放射外科小组开展了一项关于肝细胞癌肝脏病变立体定向体部放射治疗的全国性治疗模式调查，包括19个问题和2个临床病例。
韩国放射肿瘤学会的所有208名放射肿瘤学正规会员（100%）对本次调查做出了回应。其中，95名放射肿瘤学家是肝病学专家；64名医生未对肝细胞癌使用立体定向体部放射治疗，31名医生使用了立体定向体部放射治疗。大多数医生（52%）每年对≤5例肝细胞癌患者进行立体定向体部放射治疗。医生根据肿瘤大小和基线Child-Pugh分级应用立体定向体部放射治疗。所有医生都同意对Child-Pugh A级的2.8厘米肝细胞癌使用立体定向体部放射治疗，而23名医生（74%）对Child-Pugh B级患者选择立体定向体部放射治疗。19名医生（61%）对Child-Pugh A级的5厘米肝细胞癌选择立体定向体部放射治疗，只有14名医生（45%）对Child-Pugh B级患者选择立体定向体部放射治疗。另一方面，首选的剂量方案与60 Gy分三次相同。
在韩国的放射肿瘤学家中，肝细胞癌肝脏病变立体定向体部放射治疗的实践存在差异。需要进行更多前瞻性研究，以规范实践并建立韩国特异性的肝细胞癌立体定向体部放射治疗实践指南。
